Hubro Therapeutics is pleased to announce that enrolment to cohort 2 (8 subjects) is completed and that all subjects have received their initial doses in the company’s phase 1 trial with FMPV-1 in healthy volunteers. Due to the high proportion of subjects with early detected T cell mediated immune responses seen in cohort 1, cohort 2 is being conducted with the same dose as used cohort 1. To date, FMPV-1 has been very well tolerated and it is expected that the immune responses should be relevant in MSI-H colorectal and gastric cancer. Data on cohort 2 immune responses are expected in Q2.
